Cargando…

Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma

FOLFIRINOX is one of the most effective reference regimens in the 1st line treatment of locally advanced (LA) and metastatic pancreatic cancer (mPC), despite its high toxicity. We evaluated our real-life experience with “patient-tailored intent to treat FOLFIRINOX” in patients with LA or mPC compare...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ulusakarya, Ayhan, Teyar, Nahla, Karaboué, Abdoulaye, Haydar, Mazen, Krimi, Sarra, Biondani, Pamela, Gumus, Yusuf, Chebib, Amale, Almohamad, Wathek, Morère, Jean-François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494255/ https://www.ncbi.nlm.nih.gov/pubmed/31008993 http://dx.doi.org/10.1097/MD.0000000000015341

Ejemplares similares

A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer
por: Ulusakarya, Ayhan, et al.
Publicado: (2020)

Anti‐Programmed death‐1 therapy in advanced hepatocellular carcinoma: A real‐world experience
por: Al jarroudi, Ouissam, et al.
Publicado: (2021)

Anti-Programmed Cell Death Protein 1 (PD-1) Immunotherapy for Metastatic Hepatocellular Carcinoma After Liver Transplantation: A Report of Three Cases
por: Al Jarroudi, Ouissam, et al.
Publicado: (2020)

Clinical Relevance of the First Domomedicine Platform Securing Multidrug Chronotherapy Delivery in Metastatic Cancer Patients at Home: The inCASA European Project
por: Innominato, Pasquale F, et al.
Publicado: (2016)

Circadian rest‐activity rhythm as an objective biomarker of patient‐reported outcomes in patients with advanced cancer
por: Innominato, Pasquale F., et al.
Publicado: (2018)

Multicentre, interventional, single-arm study protocol of telemonitored circadian rhythms and patient-reported outcomes for improving mFOLFIRINOX safety in patients with pancreatic cancer (MultiDom, NCT04263948)
por: Bouchahda, Mohamed, et al.
Publicado: (2023)

Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5‐fluorouracil and leucovorin combination as first‐ or second‐line treatment against metastatic colorectal cancer: Results from the International EORTC 05011 Trial
por: Innominato, Pasquale F., et al.
Publicado: (2020)

Very late recurrence of Diethylstilbestrol - related clear cell carcinoma of the cervix: case report
por: Adani-Ifè, Ablavi, et al.
Publicado: (2015)

Pharmacologic modulation of 5-fluorouracil by folinic acid and high-dose pyridoxine for treatment of patients with digestive tract carcinomas
por: Machover, David, et al.
Publicado: (2021)

Pharmacologic modulation of 5-fluorouracil by folinic acid and pyridoxine for treatment of patients with advanced breast carcinoma
por: Machover, David, et al.
Publicado: (2022)

Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neoadjuvant FOLFIRINOX a Better Option?
por: Maman, Yossi, et al.
Publicado: (2023)

Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy
por: Guion-Dusserre, Jean-Florian, et al.
Publicado: (2016)

Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX
por: Kim, Jinkook, et al.
Publicado: (2021)

Clinical Value of Pharmacogenomic Testing in a Patient Receiving FOLFIRINOX for Pancreatic Adenocarcinoma
por: Velez-Velez, Lisa M., et al.
Publicado: (2018)

Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma
por: Gilabert, Marine, et al.
Publicado: (2017)

Influence of initial dose intensity on efficacy of FOLFIRINOX in patients with advanced pancreatic cancer
por: Kobayashi, Satoshi, et al.
Publicado: (2019)

Pegylated G-CSF Combined with mFOLFIRINOX for Advanced Pancreatic Cancer Patients
por: Chen, Peng, et al.
Publicado: (2019)

Quality of life of locally advanced pancreatic cancer patients after FOLFIRINOX treatment
por: van der Sijde, Fleur, et al.
Publicado: (2021)

Multiple Myeloma in Patients over 80: A Real World Retrospective Study of First Line Conservative Approach with Bortezomib Dexamethasone Doublet Therapy and Mini-Review of Literature
por: Huynh, Laurence, et al.
Publicado: (2022)

FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer
por: Adenis, Antoine, et al.
Publicado: (2021)

Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges
por: Yang, Feng, et al.
Publicado: (2019)

Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
por: Sasaki, Yasutsuna, et al.
Publicado: (2015)

Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
por: Okusaka, Takuji, et al.
Publicado: (2014)

Influence of a biliary stent in patients with advanced pancreatic cancer treated with modified FOLFIRINOX
por: Yoshikawa-Kimura, Akie, et al.
Publicado: (2022)

Pancreatic cancer and FOLFIRINOX: a new era and new questions
por: Marsh, Robert De W, et al.
Publicado: (2015)

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma
por: Péron, Julien, et al.
Publicado: (2016)

Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer
por: Sakr, Amr, et al.
Publicado: (2020)

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2020)

Cancer of Unknown Primary With Presumptive Pancreatic Cancer Treated With FOLFIRINOX
por: Inoue, Naonori, et al.
Publicado: (2021)

The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis
por: Zhang, Beilei, et al.
Publicado: (2021)

The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer
por: Wang, Zhi-Qiang, et al.
Publicado: (2019)

Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX
por: Choi, Young Hoon, et al.
Publicado: (2021)

Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma
por: Farshadi, Elham Aida, et al.
Publicado: (2021)

Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma
por: Acuna-Villaorduna, Ana, et al.
Publicado: (2022)

Neoadjuvant FOLFIRINOX Followed by Pancreatoduodenectomy for Pancreatic Cancer in Patients with Previous Transhiatal Esophagectomy for Esophageal Cancer
por: Kim, Juwan, et al.
Publicado: (2022)

Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy
por: Mortier, Victor, et al.
Publicado: (2022)

Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI
por: Nikolaou, Christos, et al.
Publicado: (2015)

Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis
por: Choi, Jin G., et al.
Publicado: (2018)

Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX
por: Kaga, Yasuhiro, et al.
Publicado: (2016)

Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients
por: Schlick, Konstantin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e5ds9qa8tvoo32k9bbtbunkceu